Korro Bio
Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data
Korro Bio; KRRO-110; Alpha-1 Antitrypsin Deficiency (AATD); RNA editing; clinical trial failure; layoffs; Novo Nordisk partnership; GalNAc platform; biotech strategy shift
Korro Bio Lays Off 20% of Workforce to Extend Runway for Genetic Medicine Trials and Novo Nordisk Partnership
Korro Bio; layoffs; biotech; genetic medicine; RNA editing; KRRO-110; Novo Nordisk; clinical trial funding; restructuring; AATD